ProfileGDS5678 / 1421005_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 63% 67% 68% 71% 66% 69% 74% 70% 69% 66% 74% 70% 68% 68% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.783663
GSM967853U87-EV human glioblastoma xenograft - Control 24.0392967
GSM967854U87-EV human glioblastoma xenograft - Control 34.1529468
GSM967855U87-EV human glioblastoma xenograft - Control 44.5730871
GSM967856U87-EV human glioblastoma xenograft - Control 53.9422866
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.2408969
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.7940674
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 34.3468270
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 44.292369
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.9789266
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 24.8058774
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 34.3572770
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 44.1519768
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 54.1395168